Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins: Pharmacologic implications

International Angiology

Volumn 23, Issue 4, 2004, Pages 346-354

  Florian Kujawski, M ^a   Hoppensteadt, D ^a   Maddineni, J ^a   Ziegler, H ^a   Fareed, J ^a  

^a NONE

Author keywords

Low molecular weight heparins; Thrombin activatable fibrinolytic inhibitor

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PARNAPARIN; PROTHROMBIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TINZAPARIN; FIBRINOLYTIC AGENT;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; HEMOSTASIS; HUMAN; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; FEMALE; IN VITRO STUDY; MALE; METABOLISM; PLASMA; REFERENCE VALUE; THROMBOSIS;

CARBOXYPEPTIDASE U; DALTEPARIN; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; PLASMA; REFERENCE VALUES; THROMBOSIS;

EID: 23044467243     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000;20:2511-8.
2. Bajzar L, Nesheim M, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998;273:2792-8.
3. Fareed J, Hoppensteadt DA, Jeske WP, Ahmad S, Bick RL. Acquired defects of fibrinolysis associated with thrombosis. Semin Thromb Hemost 1999;25:367-74.
4. Baglin TP, Carrell RW, Church FC, Esmon CT, Huntington JA. Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc Natl Acad Sci U S A 2002;99:11079-84.
5. Hoppensteadt DA, Jeske WP, Walenga JM, Fu K, Yang LH, Ing TS et al. Laboratory monitoring of pentasaccharide in a dog model of hemodialysis. Thromb Res 1999;96:115-24.
6. Ofosu FA, Fernandez F, Gauthier D, Buchanan MR. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate. Semin Thromb Hemost 1985;11:133-7.
7. Bouma BN, Marx PF, Mosnier LO, Meijers JCM. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001;101:329-54.
8. Guimaraes AHC, van Tilburg NH, Vos HL, Bertina RM, Rijken DC. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004;124:659-65.
9. Marx PF, Bouma BN, Meijers JC. Role of zinc ions in activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 2002;41:1211-6.
10. Walker JB, Hughes B, James I, Haddock P, Kluft C, Bajzar L. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro. J Biol Chem 2003;278:8913-21.
11. Marx PF, Havik SR, Marquart JA, Bouma BN, Meijers JCM. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2004;279:6620-8.
12. Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry 1999;38:6547-58.
13. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996;88:2093-100.
14. Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001;85:1-2.
15. Nesheim ME. TAFI. Fibrinolysis Proteolysis 1999;13:72-7.
16. Bajzar L, Manuel R, Nesheim E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-84.
17. Stewart RJ, Fredenburgh JC, Rischke JA, Bajzar L, Weitz JI. Thrombin-activable fibrinolysis inhibitor attenuates (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator. J Biol Chem 2000;275:36612-20.
18. Zhao L, Morser J, Bajzar L, Nesheim M, Nagashima M. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb Haemost 1998;80:949-55.
19. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998;273:27176-81.
20. Schneider M, Brufatto N, Neill E, Nesheim M. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin. J Biol Chem 2004;219:13340-5.
21. Florian-Kujawski MR, Hoppensteadt DA, Leya F, Lewis BE, Fareed J. Differential effects of low molecular weight heparins on thrombin activatable fibrinolytic inhibitor (TAFI) in patients undergoing percutaneous intervention. FASEB J 2002;16:A220.
22. Florian M, Fareed J, Hoppensteadt DA, Kereiakes KJ. Thrombin activatable fibrinolytic inhibitor (TAFI) is upregulated in patients undergoing percutaneous intervention (PCI): differential effects of low-molecular-weight heparins. Blood 2001;98: abstract 3905.
23. Juhan-Vague I, Grimaux RM, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2000;20:2156-61.
24. Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Stromqvist M et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Throm Haemost 2000;84:364-8.
25. Koschinsky ML, Boffa MB, Nesheim ME, Zinman B, Hanley AJ, Harris SB et al. Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAFI) with blood pressure. Clin Genet 2001;60:345-9.
26. Montaner J, Ribo M, Monasterio J, Molina CA, Alvarez-Sabin J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003;34:1038-40.
27. Santamaria A, Oliver A, Borrell M, Mateo J, Belvis R, Marti-Fabregas J et al. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 2003;34:2387-91.
28. Boffa MB, Hamill JD, Maret D, Brown D, Scott ML, Nesheim ME et al. Acute phase mediators modulate thrombin-activatable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. J Biol Chem 2003;278:9250-7.
29. Mosnier LO, Lisman T, van den Berg HM, Neiuwenhuis HK, Meijers JC, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001;86:1035-9.
30. Watanabe R, Wada H, Watanabe Y, Sakakura M, Nadasaki T, Mori Y et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001;104:1-6.
31. Meijers JCM, Oudijk EJD, Mosnier LO, Bos R, Bouma BN, Nieuwenhuis HK et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000;108:518-23.
32. Upchurch GR, Valeri CR, Khuri SF, Rohrer MJ, Welch GN, MacGregor H, Ragno G, et al. Effect of heparin on fibrinolytic activity and platelet function in vivo. Am J Physiol 1996;271(2 Pt 2):H528-34.
33. Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millennium. Semin Thromb Hemost 2000;26(Suppl 1):5-21.